toceranib
Sign in to saveToceranib (INN), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma. It is the first medication developed specifically for the treatment of cancer in dogs. It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.
Chemical data
- Formula
- C22H25FN4O2
- Molecular weight
- 396.5 g/mol
- IUPAC name
- 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- +396.19615426
Show 1 more fact
- P366
- medication
via Wikidata · CC0
Article
2 sectionsContents
- Veterinary uses
- References
Toceranib (INN), sold under the brand name Palladia, is a receptor tyrosine kinase inhibitor that is used in the treatment of canine mast cell tumor also called mastocytoma. It is the first medication developed specifically for the treatment of cancer in dogs. It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing tumor cells and by cutting off the blood supply to the tumor.
The most common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss, and blood in the stool.
Connections
Categories
1-Pyrrolidinyl compoundsCarboxamidesChemical articles with multiple CAS registry numbersChemical articles with multiple PubChem CIDsChemical pages without DrugBank identifierChemicals using indexlabelsDog medicationsDrugs developed by PfizerDrugs with non-standard legal statusFluoroarenesIndolesMultiple chemicals in Infobox drug